You are leaving

You have selected a link that will take you to a site maintained by a third party who is solely responsible
for its contents.

Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.

To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.

IST Program

Investigator Sponsored Trial (IST) Opportunities

Investigator Sponsored Trial Opportunities

Summit Therapeutics (“Summit”) may provide support for independent research such as Investigator Sponsored Trials (“ISTs”) that advance medical and scientific knowledge about Summit products, related therapeutic areas, or disease state areas of interest.

An IST is a study that is designed, implemented, and sponsored by an investigator / entity / group who has requested monetary funding and / or Summit materials (e.g., drug) to support the execution of a research study. ISTs include a variety of clinical studies such as interventional and non-interventional studies, as well as prospective or retrospective studies. Other types of studies that may be considered as an IST include non-clinical (animal), in-vitro and in-vivo studies. Summit may not serve as the sponsor of an IST.

Qualified researchers / investigators are requested to submit their proposals according to the instructions found on this page. Proposals are reviewed by a cross-functional Summit Scientific Review Committee that meets periodically. Summit’s decision to support a proposal will be based on its research merit and alignment with our Areas of Scientific Interest. Furthermore, Summit will also consider the expertise of the proposed sponsor, including their experience in the relevant therapeutic area, demonstrated ability to successfully conduct clinical trials, and available resources.

Summit does not provide operational support (e.g., authorship of a protocol, statistical analysis, study report, publication, site monitoring) for ISTs. Operational support for ISTs is the responsibility of the sponsor.

Please be aware that funding is limited, and submission of an application (even one that meets stated criteria) does not guarantee that funding will be granted to your organization. Summit receives many applications for support and cannot support them all.​

Areas of Scientific Interest​

Priority will be given to applications proposing to investigate ivonescimab in the following areas of interest:​

  • Cervical Cancer
  • Endometrial Cancer
  • Glioblastoma
  • Hepatocellular Carcinoma​ (HCC)
  • Melanoma
  • Mesothelioma
  • Ovarian Cancer
  • Small Cell Lung Cancer (SCLC)
  • Triple Negative Breast Cancer (TNBC)​

Summit will be accepting IST applications through October 8, 2023. Summit will reassess the areas of interest in 2024 for future IST submissions.

If you are interested in applying for an IST, please click here to Submit an Application. For any questions, please email us at

IST Request Process​

To submit an IST proposal, please click here to Submit an ApplicationA completed IST application form and the investigator’s curriculum vitae (CV) is required for consideration by Summit’s Scientific Review Committee.

Submission of a proposal requesting Summit’s support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. A formal notification regarding the status of your application will be communicated once a decision is reached. For any questions, email us at